Analysts Offer Predictions for NKTR FY2027 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Nektar Therapeutics in a research report issued to clients and investors on Tuesday, December 16th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings per share of ($7.79) for the year. HC Wainwright currently has a “Buy” rating and a $135.00 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ FY2028 earnings at ($9.93) EPS and FY2029 earnings at ($4.91) EPS.

NKTR has been the subject of several other research reports. Wall Street Zen cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday. Citigroup assumed coverage on Nektar Therapeutics in a research report on Wednesday, November 26th. They issued a “buy” rating and a $102.00 target price on the stock. BTIG Research lifted their target price on Nektar Therapeutics from $100.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Nektar Therapeutics in a research note on Monday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $111.83.

Nektar Therapeutics Stock Performance

NKTR stock opened at $46.84 on Friday. The stock’s fifty day moving average is $57.57 and its two-hundred day moving average is $40.23. The stock has a market capitalization of $952.73 million, a price-to-earnings ratio of -5.88 and a beta of 1.27. Nektar Therapeutics has a 1 year low of $6.45 and a 1 year high of $66.92.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.85) by $1.00. Nektar Therapeutics had a negative return on equity of 456.53% and a negative net margin of 192.87%.The business had revenue of $11.79 million for the quarter, compared to analyst estimates of $10.20 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its position in shares of Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the period. FNY Investment Advisers LLC increased its stake in Nektar Therapeutics by 70.6% in the 3rd quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 1,077 shares in the last quarter. Bessemer Group Inc. increased its stake in Nektar Therapeutics by 1,741.2% in the 3rd quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 1,480 shares in the last quarter. Compass Wealth Management LLC purchased a new stake in Nektar Therapeutics during the third quarter valued at about $88,000. Finally, Bayforest Capital Ltd purchased a new stake in Nektar Therapeutics during the third quarter valued at about $96,000. Institutional investors own 75.88% of the company’s stock.

Insider Activity

In other news, insider Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total value of $62,801.96. Following the transaction, the insider owned 18,971 shares of the company’s stock, valued at $1,029,745.88. The trade was a 5.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mark Andrew Wilson sold 630 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total transaction of $34,196.40. Following the sale, the insider directly owned 21,585 shares of the company’s stock, valued at approximately $1,171,633.80. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,994 shares of company stock worth $216,794 over the last 90 days. 5.25% of the stock is currently owned by company insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.